Regenerative medicine/stem cell universe stocks were down since the day started on Monday (4/18/11).
The NASDAQ dropped -29.27 (-1.06%) to 2735.38. The Dow was down 250 at one point but closed down -140.24 (-1.14%) to 12,201.59. On Wednesday, 4/18/11, depreciation ruled the day … but, we should be thankful that 6 companies had gains!
Advancing companies (6):
- Bioheart (OTCPK:BHRT) up $0.02 (11.11%) to $0.20;
- BioMimetic (BMTI) up $0.44 (3.31%) to $13.72;
- Brainstorm (BCLI) up $0.02 (7.14%) at $0.30;
- Geron (GERN) up $0.02 (0.40%) to $5.04;
- ReNeuron Group (RENE.L) up $0.10 (1.66%) to $5.82; and
- Tengion (TNGN) up $0.21 (8.23%) to $2.76.
Trading down companies (13):
- Aastrom (ASTM) down -$0.05 (-1.92%) to $2.55;
- Athersys (ATHX) down -$0.04 (-1.38%) to $2.86;
- Advanced Cell Technology (OTC: ACTC) down -$0.001 (-0.49%) to $0.181;
- BioTime (AMEX: BTX) down -$0.19 (-2.49%) to $7.44;
- Cytori (CYTX) down -$0.41 (-5.35%) to $7.25;
- ImmunoCellar Therapeutics (OTCPK:IMUC) down -$0.08 (-3.33%) to $2.32;
- International Stem Cell (OTCQB:ISCO) down – $0.06 (-5.0%) to $1.14;
- NeoStem (AMEX: NBS) down -$0.02 (-1.0%) at $1.99;
- Neuralstem (AMEX:CUR) down -$0.03 (-1.71%) to $1.72;
- Osiris (OSIR) down -$ 0.08 (-1.23%) to $6.41;
- Opexa (OPXA) down -$0.15 (-7.46%) to $1.86;
- Pluristem (PSTI) down – $0.13 (-4.33%) to $2.87; and
- StemCells (STEM) down -$0.025 (-3.18%) to $0.761.
- ThermoGenesis (KOOL) flat at $2.28.
The Bottom Line: Our universes’ and US stocks suffered their worst selloff in a month Monday after Standard & Poor’s (S&P) revised its long-term outlook on the US to negative from stable and as worry about Europe’s debt troubles intensified. The big winner was BioMimetic (BMTI) which was up $0.44 or 3.31% to $13.72. But it was the stock market, not the bond market, which took it on the chin. For every stock rising, almost 5 fell on the New York Stock Exchange, where 1B shares traded hands. In the low-interest rate and high-liquidity environment of the past two years, it’s easy to understand why stocks have performed well. But a negative outlook on U.S. debt suggests the end of easy-money policies may be closer than investors had hoped. The market has had a good run and was likely looking for a reason to turn lower. If liquidity dries up, stocks will struggle.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.